GlassScriptPhysician profile
Paul J Estrada
NPI 1659708840
$7,209.84
in general payments reported to CMS, 2019-2025
29 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $728 · 2023: $2,022 · 2024: $1,809 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,952.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.68 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,290.13 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $709.39 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.79 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $579.54 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $387.17 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $263.71 | 2022-2025 | Trintellix |
| Almatica Pharma LLC | $229.80 | 2023-2025 | Loreev Xr, Gralise |
| Lundbeck LLC | $217.36 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $216.64 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $175.05 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $168.78 | 2021-2023 | Qelbree |
| Vanda Pharmaceuticals INC. | $130.60 | 2023-2024 | Fanapt, Hetlioz |
| Tempus Ai, INC | $121.16 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $110.85 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $91.38 | 2023 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $74.22 | 2023-2024 | Jornay Pm |
| Neos Therapeutics, LP | $73.23 | 2022-2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $71.87 | 2023-2024 | Wellbutrin, Aplenzin |
| Tris Pharma INC | $59.14 | 2025 | Dyanavel Xr |
| Neuronetics, INC. | $55.45 | 2023-2024 | Neurostar Tms Therapy System |
| Indivior INC. | $44.53 | 2023-2024 | Sublocade |
| Idorsia Pharmaceuticals US INC | $35.28 | 2023-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $31.99 | 2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $29.22 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.89 | 2025 | Rexulti |
| Brainsway USA INC | $23.64 | 2023 | |
| Corium, LLC | $21.64 | 2023 | Azstarys |
| Mylan Specialty L.P. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Estrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.